评估BGJ398(一种成纤维细胞生长因子受体1-3激酶抑制剂)在携带成纤维细胞生长因子受体基因改变的晚期实体瘤患者中的效果:一项全球性I期剂量递增和剂量扩展研究结果
这项首次人体I期研究评估了口服BGJ398在携带FGFR基因改变的晚期实体瘤患者中的最大耐受剂量、II期推荐剂量、安全性、药代动力学、药效动力学和抗肿瘤活性。最大耐受剂量为每日125 mg,常见不良事件为高磷血症等;在FGFR1扩增的鳞状非小细胞肺癌和FGFR3突变的膀胱/尿路上皮癌中观察到抗肿瘤活性(7例部分缓解,其中6例确认)。
要点
- BGJ398的最大耐受剂量为每日125 mg,II期推荐剂量为服药3周停药1周方案。
- 最大耐受剂量下常见不良事件包括高磷血症(82.5%)、便秘(50.9%)、食欲下降(45.6%)和口腔炎(45.6%)。
- 在FGFR1扩增的鳞状非小细胞肺癌和FGFR3突变的膀胱/尿路上皮癌中观察到部分缓解。
核心结论
- BGJ398在最大耐受剂量/II期推荐剂量下具有可耐受且可管理的安全性特征,并在包括FGFR1扩增的鳞状非小细胞肺癌和FGFR3突变的膀胱/尿路上皮癌在内的多种肿瘤类型中显示出抗肿瘤活性。
研究设计与样本
- 这项首次人体研究分为两部分,纳入携带成纤维细胞生长因子受体(FGFR)基因改变的晚期实体瘤患者,旨在确定最大耐受剂量、II期推荐剂量以及口服BGJ398的给药方案、安全性、药代动力学、药效动力学和抗肿瘤活性。
- 成人患者接受BGJ398剂量递增治疗,剂量范围为每日5至150 mg一次或50 mg每日两次连续给药,以28天为一个周期。
- 在最大耐受剂量扩展阶段,FGFR1扩增的鳞状非小细胞肺癌患者(第1组)或其他携带FGFR基因改变(突变/扩增/融合)的实体瘤患者接受BGJ398每日连续给药(第2组)或服药3周停药1周给药(第3组)。
- 报告了来自剂量递增和扩展组的132例患者的数据(数据截止日期为2015年5月15日)。
主要发现
- 最大耐受剂量为每日125 mg,基于4例患者的剂量限制性毒性确定(100 mg组:3级转氨酶升高[n=1];125 mg组:高磷血症[n=1];150 mg组:1级角膜毒性[n=1]和3级转氨酶升高[n=1])。
- 在最大耐受剂量下治疗的患者(n=57)中,常见不良事件包括高磷血症(82.5%)、便秘(50.9%)、食欲下降(45.6%)和口腔炎(45.6%)。
- 采用服药3周停药1周方案(II期推荐剂量)时观察到相似的安全性特征,但不良事件相关的剂量调整/中断在服药3周停药1周方案(50.0%)中较连续给药方案(73.7%)更不频繁。
- 在FGFR1扩增的鳞状非小细胞肺癌和FGFR3突变的膀胱/尿路上皮癌患者中,BGJ398剂量≥100 mg时显示出抗肿瘤活性(7例部分缓解[6例确认])。
关键数值与推荐
- 最大耐受剂量为每日125 mg。
- II期推荐剂量为服药3周停药1周方案。
- 在最大耐受剂量下治疗的患者(n=57)中,高磷血症发生率为82.5%,便秘为50.9%,食欲下降为45.6%,口腔炎为45.6%。
- 不良事件相关的剂量调整/中断:服药3周停药1周方案为50.0%,连续给药方案为73.7%。
- 抗肿瘤活性:7例部分缓解(6例确认),见于FGFR1扩增的鳞状非小细胞肺癌和FGFR3突变的膀胱/尿路上皮癌患者,BGJ398剂量≥100 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients and Methods Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles. During expansion at the MTD, patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-weeks-on/1-week-off schedule (arm 3). Results Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff). The MTD, 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]). Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%). A similar safety profile was observed using the 3-weeks-on/1-week-off schedule (RP2D). However, adverse event-related dose adjustments/interruptions were less frequent with the 3-weeks-on/1-week-off (50.0%) versus the continuous (73.7%) schedule. Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer. Conclusion BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
引用
- Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2016. PMID: 27870574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。